gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · GALTHealthcarePharmaceuticals

Galectin Therapeutics Inc. (GALT)

$3.47+3.58%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$3.47▼ 38.80% in range
Nov 4, 2025Low $2.08 · High $6.51Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Galectin Therapeutics closed at $3.47 on Nov 4, up 3.58%, 46.7% below its 52-week closing high. Volume of 216.9K shares was 1.14× its 20-day average (close to normal).

Split-adjusted performance: -7.7% over one month, +54.2% over six months, -42.2% over one year.

Short interest was 9.1M shares at the Oct 15 settlement (13.7% of float, 40.0 days to cover).

Market cap$349.9M100.8M shares
Revenue · quarter$0.00—
Diluted EPS$-0.14—
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range2.08 – 6.51−46.7% from high
Volume216.9K1.14× 20-day avg
Volatility · 60d61.1%Annualised
Short % of float13.7%40.0 days to cover
Net cash-$19.8MCash $13.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −2.0%1M −7.7%3M +7.8%6M +54.2%YTD −16.6%1Y −42.2%3Y +71.8%5Y +8.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum94
Revenue growth—
Net margin—
Value (low P/E)—
Size56

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short9.1M−0.8% vs prior
Days to cover40.0Settled Oct 15
% of float13.7%
Short vol. 10d49.0%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
GALTGalectin Therapeutics$3.47+3.58%+54.2%———$349.9M
IRDOpus Genetics$4.27+8.65%−18.8%−73.8%−1072.6%—$355.2MCompare
AVIRAtea Pharmaceuticals$4.46+6.95%−21.1%———$357.7MCompare
CTNMContineum Therapeutics$9.79+1.03%−34.5%———$368.3MCompare
MPLTMapLight Therapeutics$6.71−1.47%−76.9%———$372.9MCompare
PRLDPrelude Therapeutics Incorporated$4.08+7.94%−15.7%—−244.1%—$325.6MCompare
LYELLyell Immunopharma$15.43+43.27%−26.0%−50.0%−1118875.0%—$378.1MCompare
BNTCBenitec Biopharma$9.28+10.48%−26.2%———$323.8MCompare
AVTXAvalo Therapeutics$7.07−2.48%−67.6%———$379.2MCompare

News about Galectin Therapeutics

All news →
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH CirrhosisGlobeNewswire Inc. · May 27, 2026▲ Positive

Quick answers

What does Galectin Therapeutics do?
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases.
What is GALT's market cap?
$349.95M, based on the Nov 4 close of $3.47.
Does Galectin Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of GALT is sold short?
9.1M shares, 13.7% of float, as of Oct 15, 2026.
What sector is GALT in?
Healthcare, in the Pharmaceuticals industry.

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

HQ: Norcross, GA9 employeesListed Sep 4, 2002galectintherapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology